Hematology

Artificial intelligence shows promise in improving diagnosis and treatment for patients with multiple myeloma.

Early diagnosis of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) may mitigate progression.

Treatment is typically tailored to the individuals, with HCT being the only curative treatment bone marrow failure, but long-term outcomes are generally poorer due to toxicities.

About 72% of the observed pregnancies after allogeneic hematopoietic cell transplantation occurred spontaneously, whereas remaining pregnancies were a result of assisted reproductive activities.

The humanized anti-butyrophilin 3A monoclonal antibody selectively activates Vγ9Vδ2 T-cells.

In a patient with long-shedding SARS-CoV-2, transfusion-related acute lung injury developed after intravenous immunoglobulin, emphasizing careful treatment considerations.

Researchers suggest prior treatments and follow-up duration may play a larger role.

This year the world’s first stem cell register celebrates its 50th anniversary.

Gwen Nichols, MD, discusses challenges associated with the limited access to CAR T therapy and the need to expand outpatient and community care for patients.

Experts debate over the most effective treatment pathway for Richter transformation, highlighting the risks and benefits of different cellular therapies.

Treatment advancements highlight the curative potential of bone marrow transplants and emerging gene therapies.

The evolving treatment landscape for multiple myeloma includes debates on the timing and effectiveness of CAR T-cell therapy and quadruple immunotherapy regimens.

Disease-related factors include several prognostic scoring systems, such as DIPSS, whereas patient-related factors involve age, comorbidities, spleen size, and anemia.

Surprisingly, those with overweight BMI at diagnosis did not have a poor prognosis.

Optimizing outcomes for patients with chronic myeloid leukemia (CML) requires personalized treatment, adaptive dosing, and precise genetic insights.

Jose Tinajero, PharmD, BCOP, discusses the results of a retrospective study evaluating patients with B-cell acute lymphoblastic leukemia.

Pharmacists support treatment adherence as well as monitor adverse effects, drug-drug interactions, and quality of life.

In survivors of lymphoma with fragmented transition of care, preparedness and activation for the next phase of their survivorship was lacking.

Accurate, effective screening is crucial for connecting patients with needed financial resources and support.

Aligning with previous data, the drug combination was modestly effective in patients with large B-cell lymphoma pre- and post-CAR-T-cell therapy.

CAR T-cell therapy in multiple myeloma faces challenges from the immunosuppressive cells in the tumor microenvironment.

Building off the positive results of ELM-1, the ELM-2 trial found intravenously administered odronextamab was safe and effective in patients with relapsed or refractory follicular lymphoma.

This review explores cytopenia after CAR T-cell therapy, including its risk stratification and management with growth factors, thrombopoietin-receptor agonists, and hematopoietic stem cell boosts.

Pharmacists will play an integral role in this evolving field, from patient education and monitoring AEs to new therapeutic developments and treatment protocols.

A variety of signs and symptoms of lymphoma were reported, including fever, stomach discomfort, and weight loss.

Dan Schrum discusses the integral role of pharmacy specialists in translating clinical trial results to clinical practice.

Isatuximab (Sarclisa; Sanofi) in combination with standard-of-care significantly improved progression-free survival in patients with newly diagnosed multiple myeloma.

Dan Schrum highlights the crucial role of lymphodepletion in enhancing the effectiveness of CAR T cell therapy.

Denileukin diftitox-cxdl is the only therapy approved for cutaneous T-cell lymphoma that targets IL-2 receptors in malignant T-cells and Tregs.

Replacing carmustine with cisplatin in BEAM ((carmustine, etoposide, cytarabine, and melphalan) conditioning could be more cost-effective for patients.